Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Bosutinib

Bosutinib is a dual inhibitor of the SRC and ABL kinases. It inhibits the activating autophosphorylation of Bcr-Abl in CML cells and of v-Abl in fibroblasts. At concentrations that inhibit proliferation in CML cells, this inhibits the phosphorylation of cellular proteins such as STAT5. Preclinical studies demonstrated bosutinib to have strong antiproliferative activity in human and murine CML cell lines. It also performed well in clinical trials, exhibiting high clinical efficacy, good tolerability and low toxicity in imatinib-resistant or -intolerant CML patients.

catalogue number: B097
synonyms: SKI-606
CAS: 380843-75-4
MW: 530.45 g/mol

References
Cancer Res. 2003 Jan 15;63(2):375-81. PMID: 12543790
Expert Rev Hematol. 2009 Oct;2(5):489-97. PMID: 21083014
Crystal Structure of Human Serine Threonine Kinase- 10 Bound to Bosutinib PDB: 3ZZ2